vtuking

GSK, Sanofi to agree $624 million deal with UK for COVID-19 vaccine

CORONAVIRUS

GSK, Sanofi to agree $624 million deal with UK for COVID-19 vaccine

Both GSK and Sanofi said that they are placing more priority on quality rather than speed.

 

British and French pharmaceutical giants, GlaxoSmithKline (GSK) and Sanofi are close to reaching a $624 million (500 million pounds) deal with the United Kingdom (UK) government for the supply of 60 million doses of coronavirus vaccine as many countries move for possible COVID-19 treatments.

Reports suggest that the UK was considering an option to buy the vaccine should the human trials, which are due to commence in September 2020, turn out successful.  Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated.

More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven.

The funds would be paid in stages as the vaccine progresses, with the final payment made on delivery.

In order not to be left behind, the UK government has been engaging a wide range of companies both at home and abroad to negotiate access to vaccines. They said that the right announcements of these arrangements will be made as and when agreements with any of these companies are finalized.

The British business ministry’s spokeswoman, who confirmed that the ministry is handling Britain’s supply of potential COVID-19 vaccines, said talks were going on with different parties about access to possible vaccines but didn’t confirm if GSK/Sanofi project was one of them.

According to the ministry official, ‘’The Government’s Vaccines Task Force is actively engaging with a wide range of companies both in the UK and abroad to negotiate access to vaccines.”

“Appropriate announcements of these arrangements will be made as and when agreements with any of these companies are finalized and signed.”

Sanofi is presently working on 2 possible COVID-19 vaccines, one of which uses an adjuvant made by GSK to potentially boost its efficacy. The timeline for its clinical trials is behind the likes of Moderna Inc, the University of Oxford in collaboration with AstraZeneca Plc and an alliance of BioNTech and Pfizer Inc, whose projects all made headlines by moving to human trials as early as March. Sanofi has received financial backing from the United States and caused a stir in its home base of France after its British CEO Paul Hudson signaled that Europe was being too slow in supporting work on a vaccine, hinting U.S. patients might get any vaccine it develops first.

A reliable source said that Britain was considering taking an option to buy the vaccine should it work in human trials, which are due to begin in September.

 

The EU is also seeking a deal with Sanofi, and has invited Britain to join its efforts to buy vaccines for the bloc.

($1 = 0.8011 pounds)

Both GSK and Sanofi said that they are placing more priority on quality rather than speed in developing a vaccine.

 

 

vtuking

20 Comments

  1. Profile photo ofItz Kvng Twitch

    Reply

    Very interesting

  2. Reply

    Nice Information

  3. Reply

    Thanks for the update

  4. Reply

    Good to know

  5. Reply

    That’s a good one

  6. Reply

    That’s a great move

  7. Reply

    Good

  8. Reply

    great

  9. Reply

    Good article

  10. Reply

    Hmmmm see money oo

  11. Reply

    Thanks

  12. Reply

    Tnks for this

  13. Reply

    Nice update

  14. Reply

    Nice article

  15. Reply

    This is amazing

  16. Reply

    Nice info thank for the update

  17. Reply

    good

  18. Reply

    Okay

  19. Reply

    Hmm

  20. Reply

    Interesting

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>